Inflammatory cell chemotactic accumulation

Inflammatory cell chemotactic accumulation is a complex physiological process where various immune cells, such as neutrophils, macrophages, and lymphocytes, migrate toward a chemical gradient and aggregate at sites of injury, infection, or chronic inflammation (Source: NCBI/StatPearls). This process is initiated by the release of chemoattractants—including chemokines, complement factors like C5a, and leukotrienes—which bind to specific G protein-coupled receptors on the surface of circulating leukocytes (Source: Nature Reviews Immunology). Once activated, these cells undergo a sequence of tethering, rolling, and firm adhesion to the vascular endothelium before transmigrating into the affected tissue. While essential for clearing pathogens and initiating tissue repair, the chronic or excessive accumulation of inflammatory cells is a central pathological driver in diseases such as rheumatoid arthritis, asthma, and inflammatory bowel disease (Source: NIH). This entity is generally classified as a biological process or an assay endpoint in drug discovery rather than a single molecular target (Source: PubMed). Therapeutic strategies typically focus on disrupting this process by targeting specific chemokine receptors or adhesion molecules to prevent tissue damage, though such interventions often carry risks of impaired host defense and increased susceptibility to infection (Source: StatPearls).

Other names

Leukocyte chemotaxisInflammatory cell recruitmentImmune cell infiltrationChemotactic migrationLeukocyte extravasation

Pharmacological agents reduce inflammatory cell accumulation by antagonizing chemokine receptors (e.g., CCR5, CXCR4), inhibiting adhesion molecules (e.g., integrins), or suppressing the production of chemotactic cytokines via corticosteroid-mediated transcriptional regulation.